Literature DB >> 28903151

Anterior Chamber Invasion in Retinoblastoma: Not an Indication for Adjuvant Chemotherapy.

Kummamuri V Sreelakshmi1, Anita Chandra2, Subramanian Krishnakumar3, Viswanathan Natarajan4, Vikas Khetan1.   

Abstract

Purpose: In retinoblastoma, adjuvant chemotherapy after enucleation is given in eyes with histopathological high-risk features (HRFs) to reduced mortality. Anterior chamber seeds (AC seeds) on histopathological evaluation are a contentious finding. This study attempts to determine the effect of AC seeds on the survival rate.
Methods: This is a retrospective case record review. Eyes were divided into four groups: those with neither AC seeds nor HRFs, those with only HRFs, those with only AC seeds, and those with both HRFs and AC seeds. The groups were compared for demographic and clinical features and survival curves were plotted for each.
Results: For the 212 eyes included in the study, mean age was 30.5 ± 36.8 months. Children with only AC seeds were significantly older (75.3 ± 94.6 months) (P = 0.004). Chemotherapy was administered in 81 (38.2%) of 212 eyes; 16 (13.7%) of 117 eyes without HRF and in 65 (68.4%) of 95 eyes with HRFs (P < 0.001). The survival rate at 1, 3, and 5 years was the highest for the group with only AC seeds, although the difference was not statistically significant. Conclusions: We conclude that AC seeds do not, by themselves, constitute an independent risk factor for metastasis. These children need not be treated with immediate adjuvant chemotherapy, but, instead, can be followed with regular screening for metastasis. However, AC seeds are seen in only a small proportion of enucleated eyes. A larger study would better validate our study results.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28903151     DOI: 10.1167/iovs.17-22111

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study.

Authors:  Patricia Chévez-Barrios; Ralph C Eagle; Mark Krailo; Jin Piao; Daniel M Albert; Yun Gao; Geeta Vemuganti; Mohammad Javed Ali; Vikas Khetan; Santosh G Honavar; Joan O'Brien; Ann-Marie Leahey; Katherine Matthay; Anna Meadows; Murali Chintagumpala
Journal:  J Clin Oncol       Date:  2019-09-20       Impact factor: 44.544

2.  Clinical Characteristics and Image Manifestations of a Rare Retinoblastoma with a Bone Metastasis.

Authors:  Huali Gu; Yizhuo Wang; Dongsheng Huang; Xunda Ji; Yi Zhang; Jianmin Ma; Mei Li; Weiling Zhang; Huimin Hu; Jing Li; Pinwei Zhang
Journal:  Cancer Manag Res       Date:  2022-04-26       Impact factor: 3.602

3.  Retinoblastoma Survival Following Primary Enucleation by AJCC Staging.

Authors:  Junyang Zhao; Zhaoxun Feng; Gareth Leung; Brenda L Gallie
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

4.  Retinoblastoma presenting as pseudohypopyon and preserved visual acuity.

Authors:  Andrea L Blitzer; Sidney A Schechet; Hassan A Shah; Michael P Blair
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.